About this webinar
- iPSC-derived human disease models can be scaled to support HTS efficacy campaigns through robust bioprocessing/manufacturing
- Walk through a case study that demonstrates efficient iPSC-derived cardiomyocyte scale up, HTS assay development/validation, and a phenotypic HTS campaign of over 3600 compounds from Ncardia’s “smart library”
Ncardia, will discuss the application of human iPSC-derived cell-based assays and high throughput screening for drug discovery and development. This approach enables researchers to access human disease-relevant biology earlier in the drug discovery process. They will explore a phenotypic drug screening platform composed of genetic and induced human iPSC-derived cardiac and neural disease models, controlled bioreactor-based manufacturing to enable batch sizes compatible with high-throughput screening (HTS), generation and validation of disease-relevant assays with clinically relevant readouts, and high-throughput screening using qualified disease assays.
Not available 27 March? Register now and we will let you know once the on-demand version is available to watch.
Greg Luerman, PhD
Technical Director at Ncardia
Sr.Scientist, Assay development & High throughput at Ncardia
Already Registered? Login Here